弥漫大B细胞淋巴瘤要点.ppt

GCB VS NONGCB Green等的研究发现了类似的结果，MYC/Bcl-2共表达的比例在ABC和GCB来源亚型中分别为41%和19%。 与此相反，Perry等的研究却发现MYC/Bcl-2共表达的比例在2种亚型中较为接近(GCB型为46%，ABC型为42%)，而且MYC/Bcl-2共表达只有在GCB亚型中成为独立的不良预后因素。 GCB VS NONGCB GCB DLBCL预后好, 首选R-CHOP The LySA group conducted a randomized trial demonstrating superiority of the aggressive ACVBP regimen over R-CHOP in younger patients with low-risk DLBCL; a correlative study demonstrated equivalent outcomes in GCB and nonGCB subsets indicating a potential bene?t of the aggressive regimen in the nonGCB subgroup. GCB VS NONGCB Two recently published studies have combined lenalidomide with